INTUITIVE SURGICAL INC SEC 10-Q Report

Intuitive Surgical Inc., a leader in robotic-assisted surgical systems, has released its latest Form 10-Q report, showcasing robust financial and operational performance for the three months ended March 31, 2025. The company's significant growth in revenue, profitability, and operational efficiency underscores its strong market position and strategic execution. Financial Highlights Intuitive Surgical Inc. reported impressive financial results for the first quarter of 2025:Total Revenue: $2,253.4 million, reflecting a significant increase from $1,890.6 million in the same period last year, driven by growth in both product and service revenue.Gross Profit: $1,457.7 million, up from $1,245.4 million, indicating improved profitability and cost management.Income from Operations: $578.1 million, compared to $469.4 million, showcasing strong operational performance and efficiency.Net Income: $703.7 million, a substantial increase from $547.4 million, highlighting effective cost control and revenue growth.Net Income attributable to Intuitive Surgical, Inc.: $698.4 million, up from $544.9 million, reflecting the company's strong financial health.Basic Net Income Per Share: $1.95, compared to $1.54, indicating improved earnings per share.Diluted Net Income Per Share: $1.92, up from $1.51, demonstrating enhanced shareholder value. Business Highlights The company's operational performance was equally strong, with several key highlights:Revenue Segments: The company reported revenue from three main segments: Instruments and Accessories ($1,367.7 million), Systems ($522.7 million), and Service ($363.0 million) for the three months ended March 31, 2025.Geographical Performance: U.S. revenue accounted for $1,538.2 million, while revenue from outside the U.S. (OUS) was $715.2 million for the three months ended March 31, 2025. This indicates a strong domestic market presence with significant contributions from international markets.Sales Units: The installed base of da Vinci surgical systems grew to approximately 9,902 units as of December 31, 2024, reflecting a 15% increase from the previous year. This growth is indicative of the increasing adoption of the company's robotic-assisted surgical systems.New Product Launches: The company launched the da Vinci 5 surgical system, a next-generation multi-port robotic system, which received FDA clearance in March 2024. The system is in a phased launch, with an installed base of 509 units as of March 31, 2025.Future Outlook: The company anticipates a significant increase in cost of revenues due to recently announced global tariffs, which may impact results in the second half of 2025. The company is also focused on expanding the regulatory approvals for its da Vinci SP and Ion systems in various international markets.SEC Filing: INTUITIVE SURGICAL INC [ ISRG ] - 10-Q - Apr. 23, 2025